Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18662886 | METHOD FOR EVALUATING TEA PLANT (+)-CATECHIN CONTENT | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18418913 | EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF CERTAIN CANCERS | January 2024 | June 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18394729 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | December 2023 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18535773 | MLH1 METHYLATION ASSAY | December 2023 | July 2025 | Allow | 19 | 2 | 0 | No | No |
| 18527076 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | December 2023 | August 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18513107 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | November 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18379355 | EXTRACT FROM A BODY FLUID COMPRISING A MICRO RNA | October 2023 | June 2025 | Allow | 20 | 3 | 1 | No | No |
| 18240789 | METHODS OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE | August 2023 | August 2025 | Allow | 23 | 3 | 0 | No | No |
| 18339400 | KIT, DEVICE, AND METHOD FOR DETECTING BLADDER CANCER | June 2023 | October 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18332648 | BIOMARKER PANEL AND METHODS FOR DETECTING MICROSATELLITE INSTABILITY IN CANCERS | June 2023 | August 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18328070 | STRATIFICATION AND PROGNOSIS OF CANCER | June 2023 | November 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18311703 | DETECTION AND CLASSIFICATION OF IMP CARBAPENEMASES USING REAL-TIME POLYMERASE CHAIN REACTION ASSAY | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18308706 | Methods and Compositions for Sequentially Detecting Targets | April 2023 | November 2024 | Allow | 19 | 1 | 0 | No | No |
| 18306648 | METHODS AND COMPOSITIONS FOR RISK PREDICTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF PULMONARY DISORDERS | April 2023 | April 2025 | Allow | 24 | 3 | 1 | Yes | No |
| 18249615 | METHODS OF ASSESSING RISK OF DEVELOPING A DISEASE | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18131204 | PKD MUTATIONS AND EVALUATION OF SAME | April 2023 | March 2025 | Abandon | 24 | 3 | 1 | No | No |
| 18182868 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS | March 2023 | May 2025 | Allow | 26 | 1 | 1 | No | No |
| 18023933 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18162572 | COMPOSITIONS AND METHODS OF USING RNA FRAGMENTS | January 2023 | September 2025 | Abandon | 32 | 3 | 1 | Yes | No |
| 18003658 | EPIGENETIC BIOMARKER COMPOSITION FOR DIAGNOSING DOWN SYNDROME, AND USE THEREOF | December 2022 | June 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 18055189 | MITOCHONDRIAL DNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS | November 2022 | January 2026 | Abandon | 38 | 3 | 1 | No | No |
| 17967277 | GENE AND MUTATIONS THEREOF ASSOCIATED WITH SEIZURE AND MOVEMENT DISORDERS | October 2022 | February 2025 | Allow | 28 | 4 | 1 | No | No |
| 17945832 | METHODS AND KITS FOR EVALUATING THE RISK OF DISEASES OR CONDITIONS ASSOCIATED WITH ATHEROSCLEROSIS | September 2022 | February 2026 | Abandon | 41 | 1 | 1 | Yes | No |
| 17910206 | METHOD FOR ASSESSING DIFFERENTIATION STATE OF CELLS, GELATIN NANOPARTICLES AND GELATIN NANOPARTICLE SET | September 2022 | January 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17888290 | BIOMARKERS OF ORAL, PHARYNGEAL AND LARYNGEAL CANCERS | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17739731 | POINT-OF-CARE IMMUNOASSAY FOR QUANTITATIVE SMALL ANALYTE DETECTION | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17699761 | Method Of Determining PIK3CA Mutational Status In A Sample | March 2022 | April 2025 | Allow | 37 | 0 | 0 | No | No |
| 17651793 | LONGITUDINAL MOLECULAR DIAGNOSTICS DETECT SOMATIC REVERSION MUTATIONS | February 2022 | January 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17651397 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | February 2022 | November 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17579900 | Determining Antigen-Specific T-Cells | January 2022 | March 2025 | Allow | 38 | 1 | 1 | No | No |
| 17596711 | METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS | December 2021 | February 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17539023 | NOVEL FUSION MOLECULES AND USES THEREOF | November 2021 | April 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17594567 | METHOD OF DETERMINING ENDOMETRIAL RECEPTIVITY AND APPLICATION THEREOF | October 2021 | September 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17448662 | HIGHLY SENSITIVE IMMUNOCONJUGATE, PREPARING METHOD THEREOF, IN VITRO DIAGNOSTIC REAGENT AND IN VITRO DIAGNOSTIC KIT INCLUDING THE SAME | September 2021 | September 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17437381 | CANCER DIAGNOSIS AND PROGNOSIS | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17435766 | METHOD FOR DETERMINING SIDE EFFECTS OF TRASTUZUMAB AND KIT FOR SAME | September 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17434675 | DNA METHYLATION MARKER FOR PREDICTING RECURRENCE OF LIVER CANCER, AND USE THEREOF | August 2021 | July 2025 | Allow | 47 | 3 | 0 | No | No |
| 17432813 | PROCESS FOR CLASSIFICATION OF GLIOMA | August 2021 | February 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17430877 | BIOMARKERS | August 2021 | December 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17395769 | SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PRECOCIOUS PUBERTY DIAGNOSIS OR TREATMENT PROGNOSIS PREDICTION, AND USE THEREOF | August 2021 | February 2025 | Allow | 43 | 2 | 1 | No | No |
| 17372255 | ULTRA-HIGH-THROUGHPUT ASSAY FOR TELOMERASE REPEAT ADDITION PROCESSIVITY | July 2021 | January 2025 | Allow | 42 | 2 | 1 | No | No |
| 17368610 | Methods, Compositions and Systems for Detecting PNPLA3 Allelic Variants | July 2021 | July 2025 | Abandon | 54 | 4 | 1 | No | No |
| 17418298 | METHOD FOR DETECTING POLYMERASE INCORPORATION OF NUCLEOTIDES | June 2021 | September 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17299885 | Methods for Detecting Cell Wall-Deficient Bacteria (CWDB) in Biological Samples | June 2021 | September 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17299132 | DNA METHYLATION BIOMARKERS FOR EARLY DETECTION OF CERVICAL CANCER | June 2021 | July 2025 | Allow | 49 | 3 | 1 | Yes | No |
| 17293869 | Compositions and Methods for DNA Modification Detection | May 2021 | April 2025 | Allow | 47 | 1 | 1 | No | No |
| 17179976 | METHODS OF PREDICTING AGE, AND IDENTIFYING AND TREATING CONDITIONS ASSOCIATED WITH AGING | February 2021 | August 2025 | Abandon | 54 | 4 | 0 | Yes | No |
| 17171101 | CARRIER STATUS OF ANNEXIN A5 M2 HAPLOTYPE AND OBSTETRIC RISKS | February 2021 | August 2025 | Allow | 54 | 2 | 0 | No | No |
| 17266492 | METHODS FOR MEASURING RIBOSOMAL METHYLATION AGE | February 2021 | October 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17146294 | Methods for Diagnosis of Tuberculosis | January 2021 | June 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17257932 | COMPOSITIONS FOR THERAPEUTICS PRESCREENING | January 2021 | October 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17138314 | ENZYMATIC CIRCUITS FOR MOLECULAR SENSORS | December 2020 | April 2024 | Abandon | 39 | 2 | 0 | Yes | No |
| 17256334 | HIGH THROUGHPUT ASSEMBLY OF NUCLEIC ACID MOLECULES | December 2020 | July 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17250244 | METHODS AND COMPOSITIONS RELATING TO PERSONALIZED PAIN MANAGEMENT | December 2020 | June 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17118322 | COMBINATIONS OF CELL FREE NUCLEIC ACIDS | December 2020 | March 2025 | Allow | 51 | 5 | 1 | Yes | No |
| 17114912 | METHODS AND PROBES FOR IDENTIFYING GENE ALLELES | December 2020 | December 2024 | Abandon | 48 | 4 | 1 | No | No |
| 16973407 | DEVICES AND METHOD FOR DETECTING AN AMPLIFICATION EVENT | December 2020 | November 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 17056881 | CIRCULATORY BIOMARKERS FOR PLACENTAL OR FETAL HEALTH | November 2020 | September 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 17053834 | GENOME-WIDE CLASSIFIERS FOR DETECTION OF SUBACUTE TRANSPLANT REJECTION AND OTHER TRANSPLANT CONDITIONS | November 2020 | July 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 16980812 | Non-Invasive Classification of Benign and Malignant Melanocytic Lesions Using MicroRNA Profiling | September 2020 | October 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16938847 | Methods for Detecting and Treating Idiopathic Pulmonary Fibrosis | July 2020 | November 2025 | Abandon | 60 | 3 | 2 | No | No |
| 16963479 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | July 2020 | October 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16766366 | USE OF ADIPOQ GENE EXPRESSION LEVEL FOR CLASSIFICATION OF A SUBJECT IN RISK GROUPS IN THE PROGNOSIS OR DIAGNOSIS OF TYPE II DIABETES MELLITUS | June 2020 | October 2024 | Allow | 53 | 3 | 1 | Yes | No |
| 16650258 | MOLECULAR SIGNATURES OF THREE SUB-POPULATIONS OF DERMAL FIBROBLASTS AND DERMAL EQUIVALENT COMPRISING ONE OF THESE SUB-POPULATIONS | March 2020 | July 2025 | Allow | 60 | 3 | 2 | Yes | No |
| 16636320 | USE OF IMMUNE CELL-SPECIFIC GENE EXPRESSION FOR PROGNOSIS OF PROSTATE CANCER AND PREDICTION OF RESPONSIVENESS TO RADIATION THERAPY | February 2020 | August 2025 | Allow | 60 | 4 | 2 | Yes | No |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | December 2019 | January 2023 | Abandon | 37 | 6 | 0 | No | Yes |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | December 2019 | December 2024 | Abandon | 60 | 5 | 0 | No | Yes |
| 16685439 | METHOD OF IMPROVING PREDICTION OF RESPONSE FOR CANCER PATIENTS TREATED WITH IMMUNOTHERAPY | November 2019 | September 2025 | Allow | 60 | 9 | 1 | Yes | No |
| 16610001 | THERANOSTIC TOOLS FOR MANAGEMENT OF PANCREATIC CANCER AND ITS PRECURSORS | October 2019 | September 2024 | Allow | 59 | 6 | 1 | Yes | No |
| 16499290 | COMPANION DIAGNOSTICS FOR LEUKEMIA TREATMENT | September 2019 | November 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16323490 | DNA METHYLATION BASED PREDICTOR OF MORTALITY | February 2019 | December 2025 | Abandon | 60 | 2 | 3 | No | Yes |
| 16320379 | PHASING | January 2019 | December 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16249104 | CLONAL HEMATOPOIESIS AND CYTOKINE TARGETS | January 2019 | January 2026 | Abandon | 60 | 13 | 1 | No | No |
| 15978332 | METHODS AND DEVICES FOR BONE INFECTION TREATMENT SELECTION | May 2018 | December 2018 | Allow | 7 | 1 | 0 | Yes | No |
| 15735567 | DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASE | December 2017 | January 2025 | Abandon | 60 | 6 | 1 | No | No |
| 15821960 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | November 2017 | September 2019 | Allow | 22 | 1 | 1 | Yes | No |
| 15415476 | Methods and Systems for Predicting Whether a Subject Has a Cervical Intraepithelial Neoplasia (CIN) Lesion from a Suspension Sample of Cervical Cells | January 2017 | September 2025 | Allow | 60 | 8 | 1 | No | Yes |
| 15315808 | Method and Systems for Lung Cancer Diagnosis | December 2016 | April 2020 | Allow | 40 | 1 | 2 | Yes | No |
| 14676987 | USE OF GTF21 MUTATIONS IN THE PROGNOSIS OF THYMIC CANCERS | April 2015 | June 2016 | Allow | 15 | 2 | 0 | Yes | No |
| 13997450 | METHOD FOR DIAGNOSING HEMATOLOGICAL DISORDERS | June 2013 | June 2016 | Allow | 36 | 4 | 1 | Yes | No |
| 13682303 | ASSESSMENT AND REDUCTION OF RISK OF GRAFT-VERSUS-HOST DISEASE | November 2012 | March 2015 | Allow | 28 | 2 | 1 | Yes | No |
| 13676382 | CELLULAR ARRAYS AND METHODS OF DETECTING AND USING GENETIC DISORDER MARKERS | November 2012 | November 2015 | Allow | 36 | 4 | 0 | Yes | No |
| 13516617 | DETECTION OF STREPTOCOCCUS PNEUMONIAE THROUGH MAGNETO-AMPEROMETRIC GENOSENSORS USING LYTA GENE-SPECIFIC PRIMERS AND PROBES | November 2012 | November 2015 | Allow | 41 | 3 | 1 | Yes | No |
| 13696196 | FOOD-POISONING BACTERIA DETECTION CARRIER, AND METHOD FOR DETECTING FOOD-POISONING BACTERIA | November 2012 | June 2015 | Allow | 32 | 3 | 1 | Yes | No |
| 13522348 | SET OF PROBES FOR THE DETECTION AND TYPING OF 46 HUMAN PAPILLOMAVIRUS MUCOSAL TYPES | October 2012 | March 2015 | Allow | 32 | 1 | 1 | No | No |
| 13351485 | Prognostic Signature for Colorectal Cancer Recurrence | January 2012 | August 2015 | Allow | 43 | 5 | 1 | Yes | No |
| 13245706 | MOLECULAR DIAGNOSTIC METHODS FOR PREDICTING BRAIN METASTASIS OF BREAST CANCER | September 2011 | January 2017 | Allow | 60 | 3 | 1 | Yes | No |
| 13150799 | GENE EXPRESSION PROFILING OF EGFR POSITIVE CANCER | June 2011 | November 2011 | Allow | 6 | 1 | 0 | No | No |
| 13103407 | POLARIZATION-ENHANCED DETECTOR WITH GOLD NANORODS FOR DETECTING NANOSCALE ROTATIONAL MOTION AND METHOD THEREFOR | May 2011 | February 2012 | Allow | 10 | 2 | 0 | No | No |
| 13103497 | POLARIZATION-ENHANCED DETECTOR WITH GOLD NANORODS FOR DETECTING NANOSCALE ROTATIONAL MOTION AND METHOD THEREFOR | May 2011 | March 2012 | Allow | 10 | 2 | 0 | Yes | No |
| 12994192 | NATURAL KILLER P30 (NKP30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF | November 2010 | November 2016 | Allow | 60 | 5 | 3 | Yes | No |
| 12912421 | SUSCEPTIBILITY GENE FOR ALZHEIMER'S DISEASE | October 2010 | November 2011 | Allow | 13 | 2 | 0 | Yes | No |
| 12524865 | MUTATIONS IN HUMAN UBIAD1 | April 2010 | August 2012 | Allow | 37 | 2 | 1 | Yes | No |
| 12386146 | SPLICE VARIANTS OF HUMAN IL-23 RECEPTOR (IL-23R) MRNA AND USE OF A DELTA 9 ISOFORM IN PREDICTING INFLAMMATORY BOWEL DISEASES | April 2009 | March 2012 | Allow | 35 | 2 | 1 | Yes | No |
| 12392054 | GENETIC MARKERS OF THE RISK OF DEVELOPING RESTENOSIS | February 2009 | April 2011 | Allow | 25 | 1 | 1 | No | No |
| 12370543 | GENES INVOLVED IN INTESTINAL INFLAMMATORY DISEASES AND USE THEREOF | February 2009 | November 2011 | Allow | 33 | 2 | 1 | No | No |
| 12287505 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | October 2008 | February 2010 | Allow | 17 | 1 | 0 | No | No |
| 12220761 | DETERMINING A PREDISPOSITION TO CANCER | July 2008 | August 2010 | Allow | 25 | 1 | 0 | No | No |
| 11913873 | USE OF A GIP PROMOTER POLYMORPHISM | May 2008 | June 2011 | Allow | 43 | 1 | 1 | Yes | No |
| 12102281 | Method for Typing HLA Alleles | April 2008 | February 2013 | Allow | 58 | 2 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HANEY, AMANDA MARIE.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HANEY, AMANDA MARIE works in Art Unit 1682 and has examined 103 patent applications in our dataset. With an allowance rate of 72.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner HANEY, AMANDA MARIE's allowance rate of 72.8% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by HANEY, AMANDA MARIE receive 2.96 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HANEY, AMANDA MARIE is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +41.2% benefit to allowance rate for applications examined by HANEY, AMANDA MARIE. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 26.6% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 62.5% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 27.2% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.0% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.